Related Experiment Video
Updated: Oct 5, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
Published on: May 17, 2024
[Pharmacotherapy of hypertension]
1Philipp Klee-Institut für Klinische Pharmakologie, Wuppertal. Petra.Thuermann@klinikum-wuppertal.de
Insights
Diuretics and beta-blockers are recommended as first-line hypertension treatments due to strong evidence. Results from ongoing studies on calcium-channel blockers and AT1-receptor-antagonists will inform future hypertension guidelines.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Trials
Context:
- Hypertension management involves a wide array of available drug therapies.
- Numerous randomized controlled trials (RCTs) provide robust clinical outcome data (morbidity, mortality, quality of life).
Purpose:
- To review the current evidence base for antihypertensive drug selection.
- To identify first-line treatments based on existing clinical trial data.
Summary:
- Diuretics and beta-blockers are supported by extensive evidence demonstrating beneficial effects on patient outcomes, establishing them as first-line treatments.
- Angiotensin-converting enzyme (ACE) inhibitors have evidence for specific indications only.
- Calcium-channel blockers and angiotensin II receptor blockers (AT1-receptor-antagonists) lack comprehensive outcome data, with results from ongoing endpoint studies pending.
Impact:
- Current evidence supports diuretics and beta-blockers as primary choices for hypertension management.
- Pending results from ongoing trials for calcium-channel blockers and AT1-receptor-antagonists are crucial for future guideline revisions and treatment strategies.
Abstract:
A large variety of drugs is available for treatment of hypertension. Moreover, many randomised controlled trials with clinically relevant endpoints (morbidity, mortality, quality of life) do exist in the cardiovascular field, providing for sufficient evidence to choose the appropriate agent in most circumstances. For diuretics and betablockers a large body of evidence in terms of beneficial effects on outcome does exist, for ACE-inhibitors in some special indications only. These drugs are therefore recommended as first-line treatments. For calcium-channel blockers (with the exception of isolated systolic hypertension in the elderly) and AT1-receptor-antagonists the results of endpoint-studies are still awaited. These results will have to be considered for revised versions of currently available guidelines.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension II: Pathophysiology
Antihypertensive Drugs: Action of Diuretics
Hypertension V: Nursing Management